Antiphosphatidylethanolamine antibodies as the only antiphospholipid antibodies detected by ELISA. II. Kininogen reactivity.

@article{Boffa1996AntiphosphatidylethanolamineAA,
  title={Antiphosphatidylethanolamine antibodies as the only antiphospholipid antibodies detected by ELISA. II. Kininogen reactivity.},
  author={Marie Claire Boffa and Michel B{\'e}rard and Takehiko Sugi and John McIntyre},
  journal={The Journal of rheumatology},
  year={1996},
  volume={23 8},
  pages={1375-9}
}
OBJECTIVE To study the requirement for serum and for low (LMWK) and high molecular weight kininogen (HMWK) and/or HMWK binding proteins to detect antiphosphatidylethanolamine antibodies (aPE) in ELISA. METHODS Eighteen patients with aPE (9 IgG and 13 IgM) as the only antiphospholipid antibody (aPL) detected by ELISA were assigned to 4 groups: thromboembolic episodes (TEE) (Group I, n = 6); livedo reticularis (LR) without TEE, (Group II, n = 4); both LR and thrombosis (Group III, n = 4); and… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
To study the requirement for serum and for low ( LMWK ) and high molecular weight kininogen ( HMWK ) and/or HMWK binding proteins to detect antiphosphatidylethanolamine antibodies ( aPE ) in ELISA .
To study the requirement for serum and for low ( LMWK ) and high molecular weight kininogen ( HMWK ) and/or HMWK binding proteins to detect antiphosphatidylethanolamine antibodies ( aPE ) in ELISA .
To study the requirement for serum and for low ( LMWK ) and high molecular weight kininogen ( HMWK ) and/or HMWK binding proteins to detect antiphosphatidylethanolamine antibodies ( aPE ) in ELISA .
Eighteen patients with aPE ( 9 IgG and 13 IgM ) as the only antiphospholipid antibody ( aPL ) detected by ELISA were assigned to 4 groups : thromboembolic episodes ( TEE ) ( Group I , n = 6 ) ; livedo reticularis ( LR ) without TEE , ( Group II , n = 4 ) ; both LR and thrombosis ( Group III , n = 4 ) ; and systemic lupus erythematosus ( SLE ) or primary antiphospholipid syndrome ( APS ) ( Group IV , n = 4 ) .
Eighteen patients with aPE ( 9 IgG and 13 IgM ) as the only antiphospholipid antibody ( aPL ) detected by ELISA were assigned to 4 groups : thromboembolic episodes ( TEE ) ( Group I , n = 6 ) ; livedo reticularis ( LR ) without TEE , ( Group II , n = 4 ) ; both LR and thrombosis ( Group III , n = 4 ) ; and systemic lupus erythematosus ( SLE ) or primary antiphospholipid syndrome ( APS ) ( Group IV , n = 4 ) .
Eighteen patients with aPE ( 9 IgG and 13 IgM ) as the only antiphospholipid antibody ( aPL ) detected by ELISA were assigned to 4 groups : thromboembolic episodes ( TEE ) ( Group I , n = 6 ) ; livedo reticularis ( LR ) without TEE , ( Group II , n = 4 ) ; both LR and thrombosis ( Group III , n = 4 ) ; and systemic lupus erythematosus ( SLE ) or primary antiphospholipid syndrome ( APS ) ( Group IV , n = 4 ) .
Eighteen patients with aPE ( 9 IgG and 13 IgM ) as the only antiphospholipid antibody ( aPL ) detected by ELISA were assigned to 4 groups : thromboembolic episodes ( TEE ) ( Group I , n = 6 ) ; livedo reticularis ( LR ) without TEE , ( Group II , n = 4 ) ; both LR and thrombosis ( Group III , n = 4 ) ; and systemic lupus erythematosus ( SLE ) or primary antiphospholipid syndrome ( APS ) ( Group IV , n = 4 ) .
Eighteen patients with aPE ( 9 IgG and 13 IgM ) as the only antiphospholipid antibody ( aPL ) detected by ELISA were assigned to 4 groups : thromboembolic episodes ( TEE ) ( Group I , n = 6 ) ; livedo reticularis ( LR ) without TEE , ( Group II , n = 4 ) ; both LR and thrombosis ( Group III , n = 4 ) ; and systemic lupus erythematosus ( SLE ) or primary antiphospholipid syndrome ( APS ) ( Group IV , n = 4 ) .
Eighteen patients with aPE ( 9 IgG and 13 IgM ) as the only antiphospholipid antibody ( aPL ) detected by ELISA were assigned to 4 groups : thromboembolic episodes ( TEE ) ( Group I , n = 6 ) ; livedo reticularis ( LR ) without TEE , ( Group II , n = 4 ) ; both LR and thrombosis ( Group III , n = 4 ) ; and systemic lupus erythematosus ( SLE ) or primary antiphospholipid syndrome ( APS ) ( Group IV , n = 4 ) .
Eighteen patients with aPE ( 9 IgG and 13 IgM ) as the only antiphospholipid antibody ( aPL ) detected by ELISA were assigned to 4 groups : thromboembolic episodes ( TEE ) ( Group I , n = 6 ) ; livedo reticularis ( LR ) without TEE , ( Group II , n = 4 ) ; both LR and thrombosis ( Group III , n = 4 ) ; and systemic lupus erythematosus ( SLE ) or primary antiphospholipid syndrome ( APS ) ( Group IV , n = 4 ) .
Eighteen patients with aPE ( 9 IgG and 13 IgM ) as the only antiphospholipid antibody ( aPL ) detected by ELISA were assigned to 4 groups : thromboembolic episodes ( TEE ) ( Group I , n = 6 ) ; livedo reticularis ( LR ) without TEE , ( Group II , n = 4 ) ; both LR and thrombosis ( Group III , n = 4 ) ; and systemic lupus erythematosus ( SLE ) or primary antiphospholipid syndrome ( APS ) ( Group IV , n = 4 ) .
Eighteen patients with aPE ( 9 IgG and 13 IgM ) as the only antiphospholipid antibody ( aPL ) detected by ELISA were assigned to 4 groups : thromboembolic episodes ( TEE ) ( Group I , n = 6 ) ; livedo reticularis ( LR ) without TEE , ( Group II , n = 4 ) ; both LR and thrombosis ( Group III , n = 4 ) ; and systemic lupus erythematosus ( SLE ) or primary antiphospholipid syndrome ( APS ) ( Group IV , n = 4 ) .
Eighteen patients with aPE ( 9 IgG and 13 IgM ) as the only antiphospholipid antibody ( aPL ) detected by ELISA were assigned to 4 groups : thromboembolic episodes ( TEE ) ( Group I , n = 6 ) ; livedo reticularis ( LR ) without TEE , ( Group II , n = 4 ) ; both LR and thrombosis ( Group III , n = 4 ) ; and systemic lupus erythematosus ( SLE ) or primary antiphospholipid syndrome ( APS ) ( Group IV , n = 4 ) .
Eighteen patients with aPE ( 9 IgG and 13 IgM ) as the only antiphospholipid antibody ( aPL ) detected by ELISA were assigned to 4 groups : thromboembolic episodes ( TEE ) ( Group I , n = 6 ) ; livedo reticularis ( LR ) without TEE , ( Group II , n = 4 ) ; both LR and thrombosis ( Group III , n = 4 ) ; and systemic lupus erythematosus ( SLE ) or primary antiphospholipid syndrome ( APS ) ( Group IV , n = 4 ) .
Eighteen patients with aPE ( 9 IgG and 13 IgM ) as the only antiphospholipid antibody ( aPL ) detected by ELISA were assigned to 4 groups : thromboembolic episodes ( TEE ) ( Group I , n = 6 ) ; livedo reticularis ( LR ) without TEE , ( Group II , n = 4 ) ; both LR and thrombosis ( Group III , n = 4 ) ; and systemic lupus erythematosus ( SLE ) or primary antiphospholipid syndrome ( APS ) ( Group IV , n = 4 ) .
Eighteen patients with aPE ( 9 IgG and 13 IgM ) as the only antiphospholipid antibody ( aPL ) detected by ELISA were assigned to 4 groups : thromboembolic episodes ( TEE ) ( Group I , n = 6 ) ; livedo reticularis ( LR ) without TEE , ( Group II , n = 4 ) ; both LR and thrombosis ( Group III , n = 4 ) ; and systemic lupus erythematosus ( SLE ) or primary antiphospholipid syndrome ( APS ) ( Group IV , n = 4 ) .
Eighteen patients with aPE ( 9 IgG and 13 IgM ) as the only antiphospholipid antibody ( aPL ) detected by ELISA were assigned to 4 groups : thromboembolic episodes ( TEE ) ( Group I , n = 6 ) ; livedo reticularis ( LR ) without TEE , ( Group II , n = 4 ) ; both LR and thrombosis ( Group III , n = 4 ) ; and systemic lupus erythematosus ( SLE ) or primary antiphospholipid syndrome ( APS ) ( Group IV , n = 4 ) .
Eighteen patients with aPE ( 9 IgG and 13 IgM ) as the only antiphospholipid antibody ( aPL ) detected by ELISA were assigned to 4 groups : thromboembolic episodes ( TEE ) ( Group I , n = 6 ) ; livedo reticularis ( LR ) without TEE , ( Group II , n = 4 ) ; both LR and thrombosis ( Group III , n = 4 ) ; and systemic lupus erythematosus ( SLE ) or primary antiphospholipid syndrome ( APS ) ( Group IV , n = 4 ) .
Eighteen patients with aPE ( 9 IgG and 13 IgM ) as the only antiphospholipid antibody ( aPL ) detected by ELISA were assigned to 4 groups : thromboembolic episodes ( TEE ) ( Group I , n = 6 ) ; livedo reticularis ( LR ) without TEE , ( Group II , n = 4 ) ; both LR and thrombosis ( Group III , n = 4 ) ; and systemic lupus erythematosus ( SLE ) or primary antiphospholipid syndrome ( APS ) ( Group IV , n = 4 ) .
Eighteen patients with aPE ( 9 IgG and 13 IgM ) as the only antiphospholipid antibody ( aPL ) detected by ELISA were assigned to 4 groups : thromboembolic episodes ( TEE ) ( Group I , n = 6 ) ; livedo reticularis ( LR ) without TEE , ( Group II , n = 4 ) ; both LR and thrombosis ( Group III , n = 4 ) ; and systemic lupus erythematosus ( SLE ) or primary antiphospholipid syndrome ( APS ) ( Group IV , n = 4 ) .
Eighteen patients with aPE ( 9 IgG and 13 IgM ) as the only antiphospholipid antibody ( aPL ) detected by ELISA were assigned to 4 groups : thromboembolic episodes ( TEE ) ( Group I , n = 6 ) ; livedo reticularis ( LR ) without TEE , ( Group II , n = 4 ) ; both LR and thrombosis ( Group III , n = 4 ) ; and systemic lupus erythematosus ( SLE ) or primary antiphospholipid syndrome ( APS ) ( Group IV , n = 4 ) .
Eighteen patients with aPE ( 9 IgG and 13 IgM ) as the only antiphospholipid antibody ( aPL ) detected by ELISA were assigned to 4 groups : thromboembolic episodes ( TEE ) ( Group I , n = 6 ) ; livedo reticularis ( LR ) without TEE , ( Group II , n = 4 ) ; both LR and thrombosis ( Group III , n = 4 ) ; and systemic lupus erythematosus ( SLE ) or primary antiphospholipid syndrome ( APS ) ( Group IV , n = 4 ) .
Eighteen patients with aPE ( 9 IgG and 13 IgM ) as the only antiphospholipid antibody ( aPL ) detected by ELISA were assigned to 4 groups : thromboembolic episodes ( TEE ) ( Group I , n = 6 ) ; livedo reticularis ( LR ) without TEE , ( Group II , n = 4 ) ; both LR and thrombosis ( Group III , n = 4 ) ; and systemic lupus erythematosus ( SLE ) or primary antiphospholipid syndrome ( APS ) ( Group IV , n = 4 ) .
Eighteen patients with aPE ( 9 IgG and 13 IgM ) as the only antiphospholipid antibody ( aPL ) detected by ELISA were assigned to 4 groups : thromboembolic episodes ( TEE ) ( Group I , n = 6 ) ; livedo reticularis ( LR ) without TEE , ( Group II , n = 4 ) ; both LR and thrombosis ( Group III , n = 4 ) ; and systemic lupus erythematosus ( SLE ) or primary antiphospholipid syndrome ( APS ) ( Group IV , n = 4 ) .
Eighteen patients with aPE ( 9 IgG and 13 IgM ) as the only antiphospholipid antibody ( aPL ) detected by ELISA were assigned to 4 groups : thromboembolic episodes ( TEE ) ( Group I , n = 6 ) ; livedo reticularis ( LR ) without TEE , ( Group II , n = 4 ) ; both LR and thrombosis ( Group III , n = 4 ) ; and systemic lupus erythematosus ( SLE ) or primary antiphospholipid syndrome ( APS ) ( Group IV , n = 4 ) .
Eighteen patients with aPE ( 9 IgG and 13 IgM ) as the only antiphospholipid antibody ( aPL ) detected by ELISA were assigned to 4 groups : thromboembolic episodes ( TEE ) ( Group I , n = 6 ) ; livedo reticularis ( LR ) without TEE , ( Group II , n = 4 ) ; both LR and thrombosis ( Group III , n = 4 ) ; and systemic lupus erythematosus ( SLE ) or primary antiphospholipid syndrome ( APS ) ( Group IV , n = 4 ) .
Eighteen patients with aPE ( 9 IgG and 13 IgM ) as the only antiphospholipid antibody ( aPL ) detected by ELISA were assigned to 4 groups : thromboembolic episodes ( TEE ) ( Group I , n = 6 ) ; livedo reticularis ( LR ) without TEE , ( Group II , n = 4 ) ; both LR and thrombosis ( Group III , n = 4 ) ; and systemic lupus erythematosus ( SLE ) or primary antiphospholipid syndrome ( APS ) ( Group IV , n = 4 ) .
Eighteen patients with aPE ( 9 IgG and 13 IgM ) as the only antiphospholipid antibody ( aPL ) detected by ELISA were assigned to 4 groups : thromboembolic episodes ( TEE ) ( Group I , n = 6 ) ; livedo reticularis ( LR ) without TEE , ( Group II , n = 4 ) ; both LR and thrombosis ( Group III , n = 4 ) ; and systemic lupus erythematosus ( SLE ) or primary antiphospholipid syndrome ( APS ) ( Group IV , n = 4 ) .
Eighteen patients with aPE ( 9 IgG and 13 IgM ) as the only antiphospholipid antibody ( aPL ) detected by ELISA were assigned to 4 groups : thromboembolic episodes ( TEE ) ( Group I , n = 6 ) ; livedo reticularis ( LR ) without TEE , ( Group II , n = 4 ) ; both LR and thrombosis ( Group III , n = 4 ) ; and systemic lupus erythematosus ( SLE ) or primary antiphospholipid syndrome ( APS ) ( Group IV , n = 4 ) .
Eighteen patients with aPE ( 9 IgG and 13 IgM ) as the only antiphospholipid antibody ( aPL ) detected by ELISA were assigned to 4 groups : thromboembolic episodes ( TEE ) ( Group I , n = 6 ) ; livedo reticularis ( LR ) without TEE , ( Group II , n = 4 ) ; both LR and thrombosis ( Group III , n = 4 ) ; and systemic lupus erythematosus ( SLE ) or primary antiphospholipid syndrome ( APS ) ( Group IV , n = 4 ) .
Eighteen patients with aPE ( 9 IgG and 13 IgM ) as the only antiphospholipid antibody ( aPL ) detected by ELISA were assigned to 4 groups : thromboembolic episodes ( TEE ) ( Group I , n = 6 ) ; livedo reticularis ( LR ) without TEE , ( Group II , n = 4 ) ; both LR and thrombosis ( Group III , n = 4 ) ; and systemic lupus erythematosus ( SLE ) or primary antiphospholipid syndrome ( APS ) ( Group IV , n = 4 ) .
Eighteen patients with aPE ( 9 IgG and 13 IgM ) as the only antiphospholipid antibody ( aPL ) detected by ELISA were assigned to 4 groups : thromboembolic episodes ( TEE ) ( Group I , n = 6 ) ; livedo reticularis ( LR ) without TEE , ( Group II , n = 4 ) ; both LR and thrombosis ( Group III , n = 4 ) ; and systemic lupus erythematosus ( SLE ) or primary antiphospholipid syndrome ( APS ) ( Group IV , n = 4 ) .
Eighteen patients with aPE ( 9 IgG and 13 IgM ) as the only antiphospholipid antibody ( aPL ) detected by ELISA were assigned to 4 groups : thromboembolic episodes ( TEE ) ( Group I , n = 6 ) ; livedo reticularis ( LR ) without TEE , ( Group II , n = 4 ) ; both LR and thrombosis ( Group III , n = 4 ) ; and systemic lupus erythematosus ( SLE ) or primary antiphospholipid syndrome ( APS ) ( Group IV , n = 4 ) .
Eighteen patients with aPE ( 9 IgG and 13 IgM ) as the only antiphospholipid antibody ( aPL ) detected by ELISA were assigned to 4 groups : thromboembolic episodes ( TEE ) ( Group I , n = 6 ) ; livedo reticularis ( LR ) without TEE , ( Group II , n = 4 ) ; both LR and thrombosis ( Group III , n = 4 ) ; and systemic lupus erythematosus ( SLE ) or primary antiphospholipid syndrome ( APS ) ( Group IV , n = 4 ) .
Eighteen patients with aPE ( 9 IgG and 13 IgM ) as the only antiphospholipid antibody ( aPL ) detected by ELISA were assigned to 4 groups : thromboembolic episodes ( TEE ) ( Group I , n = 6 ) ; livedo reticularis ( LR ) without TEE , ( Group II , n = 4 ) ; both LR and thrombosis ( Group III , n = 4 ) ; and systemic lupus erythematosus ( SLE ) or primary antiphospholipid syndrome ( APS ) ( Group IV , n = 4 ) .
Eighteen patients with aPE ( 9 IgG and 13 IgM ) as the only antiphospholipid antibody ( aPL ) detected by ELISA were assigned to 4 groups : thromboembolic episodes ( TEE ) ( Group I , n = 6 ) ; livedo reticularis ( LR ) without TEE , ( Group II , n = 4 ) ; both LR and thrombosis ( Group III , n = 4 ) ; and systemic lupus erythematosus ( SLE ) or primary antiphospholipid syndrome ( APS ) ( Group IV , n = 4 ) .
Eighteen patients with aPE ( 9 IgG and 13 IgM ) as the only antiphospholipid antibody ( aPL ) detected by ELISA were assigned to 4 groups : thromboembolic episodes ( TEE ) ( Group I , n = 6 ) ; livedo reticularis ( LR ) without TEE , ( Group II , n = 4 ) ; both LR and thrombosis ( Group III , n = 4 ) ; and systemic lupus erythematosus ( SLE ) or primary antiphospholipid syndrome ( APS ) ( Group IV , n = 4 ) .
Eighteen patients with aPE ( 9 IgG and 13 IgM ) as the only antiphospholipid antibody ( aPL ) detected by ELISA were assigned to 4 groups : thromboembolic episodes ( TEE ) ( Group I , n = 6 ) ; livedo reticularis ( LR ) without TEE , ( Group II , n = 4 ) ; both LR and thrombosis ( Group III , n = 4 ) ; and systemic lupus erythematosus ( SLE ) or primary antiphospholipid syndrome ( APS ) ( Group IV , n = 4 ) .
To study the requirement for serum and for low ( LMWK ) and high molecular weight kininogen ( HMWK ) and/or HMWK binding proteins to detect antiphosphatidylethanolamine antibodies ( aPE ) in ELISA .
All Topics